Stemtech Corporation (STEK) Stock Price & Analysis
Stemtech Corporation (STEK) — price $0.0001 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Stemtech Corporation · STEK
Stemtech Corporation develops and markets stem cell nutrition products aimed at supporting the body's natural renewal processes. The company operates in the dietary supplement industry, focusing on products that enhance stem cell release, circulation, and migration.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0001 | |
| Change on the day | 0.00% | |
| 52-week range | $0.00001 – $0.0033 | |
| Shares traded on the day | 10.0K |
Price & events
Other perspectives
Council score for Stemtech (STEK): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 5, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Aug 21, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Aug 21, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Stemtech (STEK), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Stemtech Corporation (STEK) is the company analyzed here. It employs 1 people and is led by Charles S. Arnold. In Q3 FY2026 it reported revenue of $282,484 and net income of -$478,575.
What do the latest results show for Stemtech (STEK)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $282,484.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $282,484 | -$478,575 | -$0.0002 (diluted) |
| Q2 FY2026 | $629,312 | -$292,358 | -$0.0001 (diluted) |
| Q1 FY2026 | $462,957 | -$1M | -$0.0015 (diluted) |
| Q4 FY2025 | $458,109 | -$1M | -$0.01 (diluted) |
What are the financial strengths and risks for Stemtech (STEK)?
Short answer · as of
The distress and quality screens read Altman Z -22.76 · Piotroski F 1. Trailing ratios: ROE 46.5% · current ratio 0.05.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -22.76 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 6
- Identified insiders
- 4
- Purchases
- 1
- Sales
- 2
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held STEK in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported STEK in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Stemtech (STEK)?
What Investors Ask About Stemtech (STEK)
These answers are editorial: 1 of these 1 answer is drawn from the STEK research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What do analysts say about STEK stock?
Given that Stemtech Corporation trades on the OTC Other tier, formal analyst coverage is unlikely. Key valuation metrics, such as the negative P/E ratio, indicate that the company is currently not profitable.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com